Biotechnology sits at one of the most contested edges of patent law, where does a natural discovery end and a human invention begin? Genes, microorganisms, and genetically modified organisms have all tested that line, and the answer differs sharply between India and the US. For biotech innovators, understanding that line early shapes how research is documented and how claims eventually get drafted.
This post covers what’s patentable in biotech, where the India-US gap is widest, where innovation is concentrated, and how a firm like PATHtoIP fits into the process.
What Makes a Biotechnology Invention Patentable
The Three Basic Tests
The same three tests apply as everywhere else: novelty, inventive step, and industrial applicability. But biotech adds a fourth hurdle in practice, proving the invention is genuinely man-made rather than an isolated or observed product of nature.
What Typically Gets Filed
- Genetically modified microorganisms and cell lines
- Recombinant DNA technology and gene constructs
- Novel processes for producing biological compounds (fermentation, cell culture methods)
- Diagnostic and research tools built on biological mechanisms
- CRISPR and gene-editing applications a fast-growing filing category
Search and Freedom to Operate
Patentability Search
Biotech patent landscapes move fast, especially in gene-editing and synthetic biology, so a search needs to be recent to be reliable, a landscape from even two years ago can already be outdated.
Freedom to Operate
FTO is especially critical when working with licensed platform technologies (like CRISPR licensing), since foundational tools are often controlled by a small number of patent holders.
India vs. the US: A Quick Comparison
| India | United States | |
| Governing law | Patents Act, 1970 | 35 U.S.C. (Patent Act) |
| Plants, animals, essentially biological processes | Excluded under Section 3(j), except microorganisms | Living organisms patentable if man-made (per Diamond v. Chakrabarty, 1980) |
| Isolated genes/DNA | Generally excluded as products of nature | Also excluded post-Myriad (2013) — naturally occurring DNA isn’t patentable, but cDNA can be |
| Microorganisms | Patentable if genuinely modified/non-naturally occurring | Patentable under the same Chakrabarty standard |
Section 3(j) is the key Indian provision, it carves out plants, animals, and “essentially biological” processes from patentability while still allowing microorganism patents. The US landmark here is Diamond v. Chakrabarty, where the Supreme Court allowed a patent on a genetically engineered bacterium, establishing that man-made living organisms could be patented. The two systems converge more than people expect on microorganisms, but diverge sharply on plants and animals.
Where Innovation Is Actually Happening
Gene Editing and CRISPR-based Therapeutics
Ongoing licensing and IP disputes here (notably the long-running Broad Institute vs. UC Berkeley CRISPR patent fight) shape how new entrants need to structure their own claims.
Synthetic Biology
Engineered organisms designed for industrial or environmental applications.
Cell and Gene Therapy
A rapidly expanding filing category, closely adjacent to pharma biologics.
Agricultural Biotechnology
Genetically modified crops India’s own Bt cotton is a well-known example of a GM crop developed and commercialized with patented trait technology.
A white space analysis is particularly valuable here given how concentrated foundational IP (like CRISPR) already is among a few major holders.
Protecting the Product from Every Angle
Patents
Cover the modified organism, construct, or process. Bt cotton’s trait technology is a real example of patented biotech IP embedded in an agricultural product sold at scale in India.
Trade Secrets
Cell line development protocols and proprietary culture conditions are frequently kept as trade secrets rather than patented, since the final product doesn’t reveal the exact process used to create it.
Trademarks
Branding for a biotech platform or product line, increasingly relevant as biotech companies move from pure research into commercialized diagnostics and therapeutics.
How PATHtoIP Helps
- Patentability searches in fast-moving biotech subfields, refreshed close to filing given how quickly the landscape shifts
- Freedom to Operate analysis, particularly around foundational platform technologies that require licensing
- Patent drafting and filing for genetically modified organisms, processes, and gene-editing applications, navigating Section 3(j) carefully for Indian filings
- Trademark filing for biotech product and platform brands
- Technology landscape analysis to identify white space in a crowded foundational-IP environment
Frequently Asked Questions
Can you patent a gene in India or the US?
Generally, no, naturally occurring genes are excluded as products of nature in both countries. Modified constructs, like cDNA in the US, can be patentable, but isolated natural DNA sequences are not.
Are genetically modified organisms patentable in India?
Microorganisms can be patented if genuinely man-made. Plants and animals, and essentially biological processes for producing them, are excluded under Section 3(j).
Why does CRISPR licensing matter for a startup working on gene editing?
Foundational CRISPR patents are concentrated among a few institutions following a long-running dispute over who invented the technology first. A startup building on CRISPR typically needs a license from the relevant patent holder before commercializing, which makes an FTO check essential early on.
Working with a modified organism, process, or gene-editing application and not sure how it’s protected? PATHtoIP can help you map it out, reach out at info@pathtoip.com.
